Article

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

Author(s):

Kristi Rosa

The FDA has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

FDA

FDA

The FDA has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).1,2

The regulatory decision is supported by data from the international, multicenter, open-label AZA-JMML-001 (NCT02447666), in which investigators examined the safety and efficacy of azacitidine vs historical controls in pediatric patients with newly diagnosed myelodysplastic syndrome or JMML before hematopoietic stem cell transplantation (HSCT).

A total of 18 study participants were administered intravenous azacitidine at a daily dose of 75 mg/m2 on days 1 through 7 of a 28-day treatment cycle for a minimum of 3 cycles and a maximum of 6 cycles. The primary end point of the trial was response rate, which was comprised of complete remission (cCR) or clinical partial remission (cPR) per International JMML response criteria, at 3 months.

Results showed that 50% of patients (95% CI, 26%-74%) experienced confirmed clinical responses with the drug. Of these patients, 3 achieved a cCR and 6 experienced a cPR.

Moreover, the median time to response was 1.2 months (range, 0.95-1.87). Ninety-four percent of patients went on to receive HSCT, and the median time to transplant was 4.6 months (range, 2.8-19).

Prior data indicated that 38% of those who required platelet transfusion were free of transfusion following the third cycle of therapy. Of the 17 patients who went on to undergo HSCT, 82% were leukemia free at a median follow-up of 23.8 months (range, 7.0-39.3).

Regarding safety, the most common effects included pyrexia, rash, upper respiratory tract infection, and anemia.

References

  1. FDA approves azacitidine for newly diagnosed juvenile myelomonocytic leukemia. News release. FDA. May 20, 2022. Accessed May 20, 2022. https://bit.ly/3Lt1VrL
  2. Niemeyer CM, Flotho C, Lipka DB, et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021;5(14):2901-2908. doi:10.1182/bloodadvances.2020004144
Related Videos
Naval G. Daver, MD,
Ann S. LaCasce, MD, MMSc
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Michael T. Tees, MD, MPH, of Colorado Blood Cancer Institute
January 12th 2025

BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies